Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Immunic, Inc. IMUX
$1.70
-$0.11 (-6.59%)
На 18:01, 12 мая 2023
+194.12%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
78816745.00000000
-
week52high
11.76
-
week52low
1.11
-
Revenue
0
-
P/E TTM
0
-
Beta
1.65115500
-
EPS
-3.85000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 12:30
Описание компании
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Aegis Capital | Buy | Buy | 08 авг 2022 г. |
| SVB Leerink | Outperform | Outperform | 03 июн 2022 г. |
| Piper Sandler | Overweight | Overweight | 18 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 07 сент 2021 г. |
| Aegis Capital | Buy | 15 апр 2021 г. | |
| SVB Leerink | Market Perform | Outperform | 21 окт 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Vitt Daniel | A | 300000 | 300000 | 02 янв 2023 г. |
| Whaley Glenn | A | 110000 | 110000 | 02 янв 2023 г. |
| Nash Duane | A | 132000 | 132000 | 02 янв 2023 г. |
| Muehler Andreas | A | 132000 | 132000 | 02 янв 2023 г. |
| Neermann Joerg | A | 100000 | 47000 | 14 дек 2022 г. |
| Neermann Joerg | A | 53000 | 35000 | 13 дек 2022 г. |
| Neermann Joerg | A | 18000 | 18000 | 23 ноя 2022 г. |
| Vitt Daniel | A | 376877 | 8000 | 22 ноя 2022 г. |
| Whaley Glenn | A | 20510 | 5000 | 07 ноя 2022 г. |
| Toernsen Monika Maria | A | 30000 | 30000 | 08 июл 2022 г. |
Новостная лента
Immunic stock rises following corporate update of clinical program progress
Proactive Investors
11 мая 2023 г. в 09:46
Immunic shares are higher Thursday after the company announced its results for the first quarter ended March 31 and issued a corporate update. "In the first quarter of 2023, we reported outstanding results from two key clinical programs.
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2023, and Provide Corporate Update
PRNewsWire
09 мая 2023 г. в 06:30
– Webcast to be Held at 8:00 am ET on May 11, 2023 – NEW YORK , May 9, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the first quarter ended March 31, 2023, including a corporate update, on Thursday, May 11, 2023, before the opening of the U.S. financial markets. A webcast will follow at 8:00 am ET.
Immunic presents data showing beneficial effects of IMU-856 on gut health at Digestive Disease Week 2023
Proactive Investors
08 мая 2023 г. в 08:17
Immunic Inc (NASDAQ:IMUX) said it has presented new clinical and pre-clinical data on the molecule IMU-856 at Digestive Disease Week (DDW) 2023 currently underway in Chicago. The presentation includes data on how IMU-856 has been shown to have a beneficial effect on gut health by helping to modulate, stabilize and enhance expression of the Sirtuin 6 (SIRT6) protein in the gastrointestinal tract.
Immunic reports positive results from part C of phase 1 clinical trial of IMU-856 in patients with celiac disease
Proactive Investors
04 мая 2023 г. в 08:16
Immunic Inc (NASDAQ:IMUX) said the results from the part C portion of its phase 1 clinical trial of IMU-856 in patients with celiac disease are positive, providing what the company believes as initial clinical proof-of-concept for an entirely new therapeutic approach to gastrointestinal disorders. The data showed that there was protection of gut architecture and reduction of gluten-induced intestinal damage, improvement of the symptoms related to gluten exposure experienced by patients, dose-dependent changes in biomarker responses and the enhancement of nutrient absorption.
Immunic Inc announces appointment of Dr Richard Rudick to board of directors
Proactive Investors
27 апр 2023 г. в 08:32
Immunic Inc (NASDAQ:IMUX) has announced the appointment of Dr Richard Rudick to its board of directors, effective April 26, 2023. The biotechnology company developing small molecule therapies for chronic inflammatory and autoimmune diseases noted that Dr Rudick is a thought leader in multiple sclerosis with decades of experience in the clinic, academia, and industry.